Pin-Hung Kuo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pin-Hung Kuo has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Chao-Lin Kuo
Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung, Taiwan
1 shared publication - Ching-Ju Tsai
Department of Biological Science and Technology, College of Biopharmaceutical and Food Sciences, China Medical University, Taichung 40402, Taiwan
1 shared publication - Han-Wen Chang
Department of Biological Science and Technology, College of Biopharmaceutical and Food Sciences, China Medical University, Taichung 40402, Taiwan
1 shared publication - Meng-Shiun Chang
Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan
1 shared publication - Ming-Ching Kao
Department of Biological Science and Technology, College of Biopharmaceutical and Food Sciences, China Medical University, Taichung 40402, Taiwan
1 shared publication - Sheng-Teng Huang
Department of Chinese Medicine, China Medical University Hospital, Taichung, Taiwan, ROC
1 shared publication
Latest Publications
- Open Access
- 8 September 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (18) , 4418
Chinese Herbal Medicine Ganoderma tsugae Displays Potential Anti-Cancer Efficacy on Metastatic Prostate Cancer Cells
Resistance to the current therapies is the main clinical challenge in the treatment of lethal metastatic prostate cancer (mPCa). Developing novel therapeutic approaches with effective regimes and minimal side effects for this fatal disease remain a priority in prostate cancer study. In the present study, we demonstrated that a traditional Chinese medicine, quality-assured Ganoderma tsugae ethanol extract (GTEE), significantly suppressed cell growth and metastatic capability and caused cell cycle arrest through decreasing expression of cyclins in mPCa cells, PC-3 and DU145 cells. GTEE also induced caspase-dependent apoptosis in mPCa cells. We further showed the potent therapeutic efficacy of GTEE by inhibiting subcutaneous PC-3 tumor growth in a xenograft model. The in vitro and in vivo efficacies on mPCa cells were due to blockade of the PI3K/Akt and MAPK/ERK signaling pathways associated with cancer cell growth, survival and apoptosis. These preclinical data provide the molecular basis for a new potential therapeutic approach toward the treatment of lethal prostate cancer progression.
- 8 September 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (18) , 4418
Open AccessChinese Herbal Medicine Ganoderma tsugae Displays Potential Anti-Cancer Efficacy on Metastatic Prostate Cancer Cells
Resistance to the current therapies is the main clinical challenge in the treatment of lethal metastatic prostate cancer (mPCa). Developing novel therapeutic approaches with effective regimes and minimal side effects for this fatal disease remain a priority in prostate cancer study. In the present study, we demonstrated that a traditional Chinese medicine, quality-assured Ganoderma tsugae ethanol extract (GTEE), significantly suppressed cell growth and metastatic capability and caused cell cycle arrest through decreasing expression of cyclins in mPCa cells, PC-3 and DU145 cells. GTEE also induced caspase-dependent apoptosis in mPCa cells. We further showed the potent therapeutic efficacy of GTEE by inhibiting subcutaneous PC-3 tumor growth in a xenograft model. The in vitro and in vivo efficacies on mPCa cells were due to blockade of the PI3K/Akt and MAPK/ERK signaling pathways associated with cancer cell growth, survival and apoptosis. These preclinical data provide the molecular basis for a new potential therapeutic approach toward the treatment of lethal prostate cancer progression.